Business Context and Reporting Period
Lifemd, Inc. (LFMD) is a direct-to-patient telehealth company operating primarily through its LifeMD and RexMD brands, offering virtual primary care, weight management, and men's health services. The company also held a majority interest in WorkSimpli, a document services platform, until its sale in November 2025. This Form 10-Q covers the quarterly period ended September 30, 2025. The filing includes revisions to previously issued financial statements for 2023, 2024, and prior 2025 quarters to correct errors related to revenue recognition and agent/principal accounting.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 (Revised) | 9M 2025 | 9M 2024 (Revised) |
|---|---|---|---|---|
| Total Revenue | $60.2 million | $53.3 million | $187.0 million | $149.3 million |
| Gross Profit | $52.8 million | $48.3 million | $163.5 million | $134.7 million |
| Gross Margin | 87.7% | 90.6% | 87.4% | 90.2% |
| Operating Loss | $(2.0) million | $(4.0) million | $(1.4) million | $(14.4) million |
| Net Loss (Common Stockholders) | $(4.6) million | $(5.4) million | $(7.9) million | $(18.8) million |
| Cash and Equivalents | $23.8 million | $35.0 million (Dec 31, 2024) | $23.8 million | $37.6 million (Sep 30, 2024) |
| Working Capital | $(15.6) million | $(15.0) million (Dec 31, 2024) | $(15.6) million | $(15.0) million (Dec 31, 2024) |
| Long-Term Debt | $0 | $9.9 million (Dec 31, 2024) | $0 | $9.9 million (Dec 31, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 13% in Q3 2025 and 25% in the nine months ended September 30, 2025, compared to the prior year periods. This growth was driven primarily by a 34% increase in telehealth revenue, specifically from LifeMD primary care subscriptions.
- Debt Extinguishment: The company repaid its entire $14.0 million outstanding principal on the Avenue Credit Facility on August 5, 2025. This resulted in a one-time loss on debt extinguishment of approximately $1.2 million recorded in Q3 2025.
- Expense Management: Operating expenses increased 5% in Q3 2025, primarily due to higher selling and marketing spend ($29.5 million) to drive subscription growth. However, general and administrative expenses decreased by $1.5 million due to lower legal fees and payroll costs.
- Financial Revisions: The company revised prior period financial statements to correct immaterial errors regarding revenue recognition (agent vs. principal) and out-of-period adjustments. These revisions impacted reported revenue, deferred revenue, and accrued expenses for 2023, 2024, and early 2025.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash of $23.8 million to be sufficient to fund operations for at least the next 12 months. The company has $44.6 million remaining capacity under its At-The-Market (ATM) sales agreement.
- Strategic Shift: On November 4, 2025 (subsequent event), the company sold its majority interest in WorkSimpli to Lion Buyer, LLC for an enterprise value of approximately $65.0 million. This positions Lifemd as a pure-play telehealth company.
- Internal Controls: The company identified a material weakness in internal controls related to the recording of net revenue as an agent in arrangements with third-party pharmacy providers. This weakness existed as of December 31, 2024, and through September 30, 2025, leading to the restatement of prior periods. Management is implementing remediation plans including enhanced system reporting and reconciliation processes.
- Legal Proceedings: A putative class action lawsuit was filed in August 2025 alleging violations of the Securities Exchange Act. Additionally, a class action settlement regarding the RexMD brand was approved in September 2025, with a liability of approximately $1.1 million recorded.
Investor Verification Checklist
- Restatement Impact: Verify the specific adjustments made to prior period revenue and deferred revenue balances due to the agent/principal accounting error correction.
- WorkSimpli Sale Terms: Review the details of the WorkSimpli sale, specifically the $28.0 million contingent consideration based on future performance targets and the timing of cash receipt.
- Internal Control Remediation: Monitor the progress of the remediation plan for the material weakness in revenue recognition controls to ensure future financial reporting accuracy.
- Debt-Free Status: Confirm the company remains debt-free following the August 2025 repayment of the Avenue Facility and assess the impact on future interest expense.
- Legal Exposure: Track the status of the August 2025 shareholder class action lawsuit and any potential financial impact beyond the settled RexMD matter.